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Abstract 15 
Ability to non-invasively differentiate malignant from non-malignant abdominal masses would 16 
aid clinical decision-making. The aim of this retrospective, cross-sectional study was to identify 17 
features in dual-phase computed tomographic (CT) studies that could be used to distinguish 18 
malignant from non-malignant hepatic and splenic masses in dogs. Medical records were 19 
searched for dogs that had an abdominal dual-phase CT examination, a hepatic or splenic mass, 20 
and subsequent histopathologic diagnosis. CT images were acquired prior to and <30s (early 21 
phase) and >60s (delayed phase) after intravenous contrast administration. Fifty-two dogs with 22 
55 masses were studied: 24 hepatic, including 14 (58%) malignant and 10 (42%) non-malignant; 23 
31 splenic, including 18 (58%) malignant and 13 (42%) non-malignant. There was substantial 24 
overlap in the pre- and post-contrast CT features of malignant and non-malignant hepatic and 25 
splenic masses. Regardless of histologic diagnosis, hepatic masses most frequently showed 26 
marked, generalized enhancement in early phase images that persisted in the delayed phase. 27 
Splenic hemangiosarcoma and nodular hyperplastic lesions most frequently showed marked, 28 
generalized enhancement in early phase images that persisted in delayed images whereas most 29 
splenic hematomas had slight enhancement in early phase images. All splenic hematomas and 30 
77% of the hemangiosarcomas had contrast accumulation compatible with active hemorrhage. 31 
There were no other significant differences in quantitative or categorical CT data between 32 
malignant and non-malignant hepatic or splenic masses. Dual-phase CT of dogs with hepatic or 33 
splenic masses provides limited specific diagnostic information.  34 
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Introduction 35 
Hepatic and splenic masses are encountered frequently in dogs and reflect a range of 36 
pathological conditions including malignant neoplasia such as hepatocellular carcinoma and 37 
hemangiosarcoma, benign neoplasia such as hepatocellular adenoma and non-neoplastic 38 
conditions such as hepatic nodular hyperplasia and hematoma.1-6 Optimal management depends 39 
on accurate diagnosis and staging.7 Ability to non-invasively differentiate malignant from non-40 
malignant masses would aid clinical decision-making.  41 
In humans with a suspected hepatic mass, multi-phase computed tomographic (CT) protocols 42 
have been used to examine the pattern of enhancement of hepatic lesions following 43 
administration of intravenous contrast medium.8,9 The purpose of multi-phase CT protocols is to 44 
reveal differences in the vascular supply to lesions that reflect features of diagnostic significance. 45 
For example, hypervascular hepatic lesions (such as neoplasms with marked neovascularization) 46 
derive their blood supply primarily from the hepatic artery, so show relatively marked contrast 47 
uptake in early post-contrast CT images.8-10 Hypovascular lesions (such as metastases with 48 
necrosis) generally show reduced contrast uptake compared to the surrounding liver in late post-49 
contrast CT images.8,9 However, differentiation of malignant and non-malignant hepatic lesions 50 
using contrast uptake characteristics is complicated because non-malignant lesions (such as 51 
hepatic nodular hyperplasia) may also show signs of early marked contrast uptake followed by 52 
reduced uptake in later images, which mimics the appearance of malignant neoplasms.8  53 
In conscious humans, peak opacification of the hepatic arteries occurs at 15-25s, peak 54 
opacification of the portal veins occurs at 45-55s, and peak opacification of the hepatic veins 55 
occurs at 60-70s after the start of contrast medium injection.8,11 Triple-phase CT protocols, 56 
involving images acquired during the early and late hepatic arterial phase and the portal phase 57 
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were studied because of the potential for increased accuracy of diagnosis9,12,13, but it was found 58 
that acquiring two arterial phases carried no significant advantage.14,15 Triple-phase CT protocols 59 
are now used less frequently in human clinical practice than a dual-phase approach involving an 60 
hepatic artery-dominant phase (HAP) and a portal venous-dominant phase (PVP) with CT 61 
images acquired using time delays of 30-35s and 60-65s after the start of intravenous injection, 62 
respectively.8,14-17 In dual-phase CT protocols to examine the liver, images are acquired after 63 
peak vessel opacification because contrast accumulation in parenchymal lesions occurs after 64 
peak vessel opacification.8,11,14 Additional delayed phase images at 180s are recommended by 65 
some authors18 but are considered low-yield by others.19  In general, HAP images aid detection 66 
of hypervascular hepatic lesions8,12-16 whereas PVP images and delayed images help characterize 67 
certain hepatic lesions, such as hemangiomas, and aid detection of active hemorrhage.20 68 
Dogs with hepatic masses have not been investigated using dual-phase CT. Instead, triple-phase 69 
CT studies have been described, with images acquired at 13-20s (HAP), 30-40s (early PVP), and 70 
120s (equilibrium or delayed phase) following contrast administration.21,22  These studies found 71 
evidence of associations between the pattern and degree of post-contrast enhancement and the 72 
pathologic diagnosis of hepatic masses, although there was substantial overlap.21,22  Most 73 
hepatocellular carcinomas showed heterogeneous enhancement in HAP, PVP and delayed phase 74 
images, often had a central zone of hypoattenuation, and were hypoattenuating compared to the 75 
liver in portal and delayed phase images.21,22 Hepatic adenomas were more likely to show diffuse 76 
enhancement in HAP images and to retain contrast in PVP images.21 Hepatic hyperplastic 77 
nodules were relatively homogeneous, frequently showed marked enhancement in HAP and PVP 78 
images, and isoattenuation  compared to adjacent normal liver in delayed phase images.21,22  In 79 
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one study, hepatic metastases consistently appeared homogenous with hypoattenuation compared 80 
to the liver in all post-contrast CT images.22  81 
Multi-phase CT imaging of canine splenic masses has not been reported. A single-phase CT 82 
study of splenic masses in dogs used images acquired prior to and approximately 60s after 83 
intravenous contrast administration.23  It was found that malignant lesions, mainly 84 
hemangiosarcoma, had lower attenuation than non-malignant masses in pre-contrast images and 85 
enhanced less than surrounding splenic parenchyma in post-contrast images.23  86 
The aim of the present study was to review post-contrast CT images acquired using a dual-phase 87 
protocol in a series of dogs with histopathologically-confirmed hepatic or splenic masses in order 88 
to identify features that could be used to distinguish malignant from non-malignant masses. The 89 
term non-malignant is used here to encompass benign neoplasms and non-neoplastic mass 90 
lesions.  91 
 92 
Materials and Methods 93 
Records of the Queen Mother Hospital for Animals of The Royal Veterinary College in the 94 
period 2008-2014 were reviewed in a retrospective, cross-sectional study. Inclusion criteria were 95 
dogs that had a dual-phase, post-contrast CT study of the abdomen and subsequent 96 
histopathologic diagnosis of an hepatic or splenic mass. For the purposes of this study, mass was 97 
defined as a focal parenchymal lesion with displacement of adjacent structures and >10mm 98 
maximal transverse dimension. Dogs in which the CT examination and histological diagnosis 99 
were separated by 30 days or more were not included. Dogs in which diagnosis was based on 100 
cytology were not included.  101 
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CT scans were routinely performed in anaesthetized or sedated patients in sternal recumbency. 102 
All scans were obtained using a 16-slice MDCT scanner (MX 8000 IDT, Philips Medical 103 
Systems, Cleveland, USA). CT settings were helical acquisition, slice thickness 3mm, image 104 
reconstruction interval 1.5mm, helical pitch 0.688, tube rotation time 0.75s, x-ray tube current 105 
150 mAs, x-ray tube potential 120kVp, field of view 400mm, matrix 512x512, and medium 106 
frequency (‘soft tissue’) reconstruction algorithm. Scans were performed in a cranial to caudal 107 
direction starting at the cardiac apex and terminating at the mid-femoral diaphysis.  108 
Post-contrast CT scanning followed a dual-phase protocol introduced at our institution in 2008 109 
for all dogs having abdominal CT examinations, except those with suspected portosystemic 110 
shunting. In each dog, 2ml/kg of iohexol 300mg/ml (Omnipaque 300, GE Healthcare, Oslo, 111 
Norway) was injected intravenously at 2ml/s (maximum pressure 150 psi) using a power injector 112 
(Stellant, Medrad Inc., Pennsylvania, USA) via a catheter in a cephalic or saphenous vein. 113 
Images of the whole abdomen were acquired prior to, within 30 seconds (early phase) and at 114 
least 60 seconds (delayed phase) following the start of intravenous injection of contrast, as 115 
described for dual-phase CT protocols for humans.8,14-17 . The variable need for entry of the 116 
anesthetist into the CT room to examine their patient after the first post-contrast CT acquisition 117 
contributed to variations in the timing of the second post-contrast acquisition, which was 118 
initiated only after all personnel had exited the CT room.  119 
CT images were reviewed by a Board-certified radiologist (PM) who was blinded to the final 120 
diagnosis. The reviewer evaluated only transverse images. Where multiple CT examinations 121 
were available for a dog, only the first examination was reviewed because later studies were 122 
generally obtained after biopsy of the mass, surgery or other treatment. Dogs were excluded if 123 
review of their CT images found multiple hepatic or splenic lesions with differing imaging 124 
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features. This was considered necessary in order to be able to relate the biopsy result in each dog 125 
with the corresponding features in CT images.  126 
The following patient information was recorded: Site of mass (hepatic/splenic), diagnosis, age at 127 
time of study, breed, sex and weight. The catheter site used for contrast administration was also 128 
recorded.   129 
Commercially available software (OsiriX, Pixmeo, SARL, 266, Rue de Bernex, CH-1233, 130 
Bernex, Switzerland) was used for image review and analysis. Window width was 400 131 
Hounsfield units (HU), window level was 60 HU. Aortic and portal vein attenuation in early  and 132 
delayed phase images was recorded. The maximal transverse dimension of each mass was 133 
measured using electronic calipers.  Normal attenuation value of hepatic/splenic parenchyma was 134 
determined based on the mean of three 20mm2 regions of interest (ROIs). Attenuation of masses 135 
was measured using the maximum circular ROI that could be fitted to each mass. Identical ROIs 136 
were used for measurements in pre-contrast images and early and delayed phase images. In pre-137 
contrast CT images, hyperattenuation was defined as at least 10HU greater than normal 138 
parenchyma; hypoattenuation was defined as at least 10HU less than normal parenchyma; 139 
isoattenuation was defined as attenuation within 10 HU of normal parenchyma.22  140 
The following quantitative variables were recorded: maximal transverse dimension of the mass 141 
(mm), mean hepatic/splenic parenchymal attenuation pre-contrast (HU), attenuation of lesion 142 
pre-contrast (HU), relative attenuation of lesion (lesion attenuation – mean hepatic/splenic 143 
parenchymal attenuation), attenuation of lesion in early phase (HU), early enhancement of lesion 144 
(attenuation of lesion in early phase – attenuation of lesion pre-contrast), delayed attenuation of 145 
lesion (HU), delayed enhancement of lesion (delayed attenuation of lesion – pre-contrast 146 
attenuation of lesion) and contrast accumulation within the lesion (delayed enhancement of 147 
 8 
lesion – early enhancement of lesion). Slight enhancement was defined as <10HU; marked 148 
enhancement was defined as ≥ 10 HU.  149 
The following subjective categorical variables were recorded: appearance of the margin of mass 150 
(distinct/indistinct), parenchymal homogeneity of mass in pre-contrast images 151 
(homogenous/heterogeneous), hepatic or splenic capsular distortion as a result of mass effect 152 
(yes/no), pattern of contrast enhancement (generalized /peripheral), presence of peritoneal fluid 153 
(yes/no), mineralization within mass (yes/no), and presence of abnormal hepatic and/or splenic 154 
lymph nodes (yes/no). 22,24  155 
Tissue for histological analysis was acquired by ultrasound-guided tissue core biopsy using 14G 156 
or 18G needles, wedge resection at exploratory laparotomy, partial hepatectomy or splenectomy. 157 
All histopathologic specimens were reviewed by a Board-certified pathologist (SLP).   158 
Normality of continuous data was assessed by visual inspection and the Kolmogorov-Smirnov 159 
test. Data did not conform to a Normal distribution, hence differences were tested using a Mann-160 
Whitney U-test. Likelihood ratios (LR) and their 95% confidence intervals (95% CI) were 161 
calculated to describe the strength of associations between categorical features and malignancy. 162 
Statistical tests were performed using commercially available (SPSS version 16, SPSS Inc., 163 
Chicago, Illinois, USA) and online software (Stats calculator, Centre for Evidence Based 164 
Medicine, Toronto, Canada, http://ktclearinghouse.ca/cebm/practise/ca/calculators/statscalc).  165 
 166 
Results 167 
Fifty-two dogs with 55 masses were included: 24 had an hepatic mass, 31 had a splenic mass, 168 
and 3 dogs had both a hepatic and splenic mass (2 dogs had primary splenic hemangiosarcoma 169 
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with metastasis to the liver, and one dog had primary splenic spindle cell sarcoma with 170 
metastasis to the liver). Dogs were 11 mixed breed, 7 Labrador retrievers, 5 German shepherd 171 
dogs, 3 Flat-coated retrievers, 2 Boxers, 2 Golden retrievers, 2 Schnauzers and 2 West highland 172 
white terriers and 1 each of the following breeds: Beagle, Bernese mountain dog, Border collie, 173 
Border terrier, Bulldog, Cairn terrier, Chow Chow, Cocker spaniel, Dachshund, Dog-de-174 
Bordeaux, English springer spaniel, Irish setter, Lhasa Apso, Lurcher, Papillon, Rhodesian 175 
ridgeback, Tibetan terrier, and Yorkshire terrier. Thirty-two dogs were male (20 neutered) and 20 176 
were female (19 neutered). Their median age was 10 years (range 3 – 15 years). 177 
Median patient weight was 24kg (4-54kg). Cephalic catheters were used to administer contrast in 178 
49 (94%) dogs and saphenous catheters were used in 3 (6%) dogs.  In every dog, acquisition of 179 
early phase images occurred less than 30s after the administration of contrast. The median delay 180 
between contrast administration and delayed phase image acquisition was 120s (range 62-465s). 181 
Median aortic attenuation was 207HU (range 110-607HU) in early phase images and 130HU 182 
(range 49-219HU) in delayed phase images. Median portal attenuation was 155HU (range 48-183 
315HU) in early phase images and 129HU (range 49-226HU) in delayed phase images.  184 
Of the 24 hepatic masses, 14 (58%) were malignant (9 carcinoma, 3 metastatic splenic 185 
hemangiosarcomas, 1 metastatic splenic spindle cell sarcoma, 1 hemangiosarcoma) and 10 186 
(42%) were non-malignant (6 adenoma, 3 nodular hyperplasia, 1 bile duct hyperplasia). Of the 187 
31 splenic masses, 18 (58%) were malignant (13 hemangiosarcomas, 3 sarcomas, 1 histiocytic 188 
sarcoma, 1 metastatic renal nephroblastoma) and 13 (42%) were non-malignant (8 hematomas, 5 189 
nodular hyperplasia).  190 
There were no significant differences in quantitative or categorical CT image data between 191 
malignant and non-malignant masses in the liver (Tables 1 & 2) or spleen (Tables 3 & 4). 192 
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Similarly, there was substantial overlap in the pre- and post-contrast imaging features of the most 193 
prevalent types of hepatic and splenic masses (Tables 5 & 6, respectively). Recognizing that the 194 
wide variation in vascular attenuation observed in this study could potentially obscure 195 
differences between types of hepatic and splenic masses, the analyses were repeated after 196 
removing data for 8 dogs with delayed phase images >240s after administration of contrast and 197 
the 3 dogs with saphenous catheters; however, the significance of results of statistical tests were 198 
unchanged, hence these dogs were retained.  199 
Hepatic carcinoma, hepatic nodular hyperplasia and hepatic adenoma most frequently had lower 200 
attenuation and were heterogeneous compared to surrounding hepatic parenchyma in pre-contrast 201 
images, and the majority of these lesions showed marked, generalized enhancement in the early 202 
phase images that persisted in the delayed phase (Figure 1). The majority of hepatic masses 203 
lacked contrast accumulation. Splenic hemangiosarcoma, hematoma, and nodular hyperplastic 204 
masses were mostly slightly heterogeneous with mean attenuation similar to adjacent splenic 205 
parenchyma in pre-contrast images. In early and delayed phase images, splenic 206 
hemangiosarcoma and nodular hyperplastic lesions most frequently showed marked, diffuse 207 
enhancement in early phase images that persisted in delayed images. Most splenic hematomas 208 
had slight enhancement in early phase images but marked enhancement in delayed images, as a 209 
result of contrast accumulation (Figure 2).  210 
 211 
Discussion 212 
In the present study, no CT features were found to be significantly associated with malignant or 213 
non-malignant hepatic masses. The most prevalent of the hepatic masses studied – hepatic 214 
carcinoma, adenoma, and nodular hyperplasia – each had a similar range of CT features. Most 215 
 11 
frequently these masses were heterogeneous compared to surrounding hepatic parenchyma in 216 
pre-contrast images, and the majority of these lesions showed marked, generalized enhancement 217 
in the early phase images that persisted in the delayed phase. 218 
The present study employed a dual-phase CT protocol comparable to dual-phase CT protocols 219 
used for assessment of hepatic lesions in humans.8,14-17 There are no other reports of veterinary 220 
studies that used the same dual-phase CT protocol for assessment of hepatic or splenic masses. 221 
Two recent studies employed triple-phase CT protocols with images acquired at 13-20s (HAP), 222 
30-40s (early PVP) and 120s (delayed phase) following contrast administration.21,22  Compared 223 
to these, the early phase in the dual-phase CT protocol is similar to the early PVP, and the 224 
delayed phase is similar to the delayed phase of triple-phase CT. Omission of HAP images is 225 
unlikely to significantly reduce ability to distinguish types of hepatic mass because in previous 226 
series a large proportion of masses had similar degrees of post-contrast enhancement in HAP and 227 
PVP images.21,22 228 
In HAP images, enhancement of tissues represents contrast medium within the intravascular 229 
space and the degree of enhancement is determined primarily by the hepatic arterial blood 230 
flow.10 Subsequent tissue enhancement represents additional delivery of contrast via the portal 231 
vessels and passage of contrast material from the intravascular to the extravascular space across 232 
the capillary basement membrane, hence the degree of tissue enhancement also depends on blood 233 
volume and permeability of capillaries.10 Based on previous studies in humans16 and dogs21,22, 234 
hepatic masses containing relatively well-differentiated hepatocytes tend to enhance most 235 
strongly in HAP images, probably reflecting both their relatively abundant arterial blood flow 236 
and lack of necrotic or hemorrhagic (vascular) components. However, these observations do not 237 
represent differences that enable different histologic types of hepatic masses to be distinguished 238 
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clinically because – as observed in the present study – marked enhancement in early phase 239 
images occurs with malignant neoplasia, such as hepatocellular carcinoma, and with non-240 
malignant lesions, such as hepatic adenoma and nodular hyperplasia.21,22  241 
Differentiation of hepatocellular carcinoma from hepatic adenoma and hepatic nodular 242 
hyperplasia depends on histopathology.25,26 Hepatic carcinomas contain pleomorphic hepatocytes 243 
arranged in irregular trabeculae separated by loose vascular (sinusoidal) spaces and a variable 244 
amount of fibrous connective tissue, and exhibit varying degrees of internal hemorrhage and 245 
necrosis. Sinusoidal invasion beyond a fibrous capsule or pseudocapsule and/or intrahepatic 246 
metastasis are the key histologic criteria of hepatocellular carcinoma, but the former may be 247 
subtle and/or focal in a well-differentiated tumor. Hepatic adenomas contain well-differentiated 248 
hepatocytes in rough cords and near normal architecture, but lack portal triads or central veins. 249 
Hepatic hyperplastic nodules contain well-differentiated hepatocytes with slightly reduced 250 
numbers of portal triads or central veins compared to normal liver, but with a distorted lobular 251 
architecture and frequent vacuolar changes representing glycogen or lipid accumulation. It is 252 
important to note that the histologic diagnosis of these hepatic lesions depends on cellular and 253 
architectural features that exist in a spectrum of severity in which the boundaries between well-254 
differentiated hepatocellular carcinoma and adenoma, and between adenoma and nodular 255 
hyperplasia, are not always clearly defined. 25,26  Consequently, there will be a limit to the degree 256 
that CT features, which primarily represent non-specific gross pathologic features, such as 257 
pseudoencapsulation, hemorrhage and necrosis27, can be used to deduce the histologic diagnosis 258 
of hepatic masses. The lack of significant differences in CT features associated with malignant or 259 
non-malignant hepatic masses observed in the present study likely reflects this limitation.  260 
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Splenic hemangiosarcoma, hematoma, and nodular hyperplastic masses also exhibited variable 261 
CT features. In pre-contrast images, most splenic masses were slightly heterogeneous, with 262 
median attenuation similar to adjacent parenchyma. In early and delayed phase images, splenic 263 
hemangiosarcoma and nodular hyperplastic lesions most frequently showed marked, generalized 264 
enhancement in early phase images that persisted in delayed phase images. These results do not 265 
corroborate those of a previous study in which malignancy of a splenic mass was associated with 266 
hypoattenuation in pre-contrast images and minimal contrast accumulation in post-contrast 267 
images, with 55HU in post-contrast images representing a threshold value to distinguish 268 
malignant (<55HU) from non-malignant (>55HU) masses.23 In the present study, there was no 269 
difference in median enhancement in delayed phase images between malignant and non-270 
malignant splenic masses with both types of mass having a wide range of post-contrast 271 
attenuation values that spanned 55HU.  272 
Most splenic hematomas had slight enhancement in early phase images, and all hematomas had 273 
contrast accumulation in delayed phase images. This feature could represent active hemorrhage 274 
occurring during the CT examination20, but was not unique to hematomas as it was also observed 275 
in the majority of hemangiosarcomas. Marked focal contrast accumulation in hemangiosarcomas 276 
was reported recently, possibly representing contrast medium in wide vascular spaces within 277 
these tumors.28 Splenic malignant neoplasms, most of which are hemangiosarcomas, frequently 278 
contain extensive hemorrhage or necrosis and so may be difficult to distinguish from hematoma 279 
on the basis of either gross or histologic examination.3,29-31 As noted above with respect to 280 
hepatic masses, other imaging techniques that depict vascularity of tissues also have limited 281 
potential to distinguish the histologic types of splenic mass.32-35 282 
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The present study is subject to patient selection bias because of the requirement for histologic 283 
diagnosis, which necessitated biopsy. Lesions suspected to be malignant were more likely to be 284 
considered priorities for biopsy than lesions suspected to be benign (e.g. because they appeared 285 
unrelated to clinical signs or were known to be static), hence benign masses may be 286 
underrepresented compared to the overall number of masses encountered in the clinical setting. 287 
Similarly, hepatic or splenic masses that are routinely diagnosed in our hospital on the basis of 288 
cytologic and flow cytometric findings, primarily round cell neoplasms, were not included.  289 
Patient factors, the method of contrast injection, and timing of CT image acquisition affect the 290 
magnitude of enhancement of tissues observed following intravenous contrast administration.11,17 291 
Patient body weight and cardiac output will affect the time of the peak plasma concentration of 292 
contrast medium even if the iodide concentration of the contrast agent, its dose and rate of 293 
injection all remain constant.11,17 Injection duration is the most important injection factor to be 294 
considered for determining CT scan timing because it directly affects the time to peak contrast 295 
enhancement in an organ or vessel.11,17 With an increased duration of contrast injection, the time 296 
to peak opacification increases. For example, the protocol used in the present study with an 297 
injection rate 2ml/s will result in a slightly later peak hepatic arterial opacification than that 298 
observed using 5ml/s.36 Also, in the present study, both early and delayed post-contrast images 299 
were acquired in a cranial to caudal direction whereas the early phase may also be acquired in a 300 
caudal to cranial direction.36  301 
Variations in the degree of vascular enhancement were evident in the present study. Although 302 
acquisition of early phase images always occurred less than 30s after the start of intravenous 303 
injection of contrast, there was a wide range of values for aortic attenuation in early phase 304 
images. This range will include animals imaged near the peak of aortic enhancement and those 305 
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imaged after the peak, when portal vein attenuation is rising. Early phase images to examine the 306 
liver are acquired after peak arterial enhancement because contrast accumulation representing the 307 
hepatic arterial supply to parenchymal lesions will necessarily continue after peak arterial 308 
attenuation.8,11,14 This is a different technique to that employed for studies focused on vascular 309 
anatomy, such as investigation of portosystemic shunting37,38, when it is important to time the CT 310 
acquisition to coincide with peak vascular attenuation. The finding that portal attenuation was 311 
increased in early phase images in the present study is to be expected because portal attenuation 312 
normally exceeds hepatic arterial attenuation within 30s in anaesthetized dogs.36 Conversely, the 313 
finding of persistently high aortic attenuation in some delayed phase images suggests that other 314 
factors, such as slow circulation time and/or reduced renal excretion of contrast, possibly 315 
associated with anesthesia, may have affected some dogs. The rate of change of vascular and 316 
parenchymal contrast enhancement is most rapid soon after contrast injection and slows 317 
subsequently11, hence variations in timing of delayed phase images may have less effect on 318 
contrast accumulation in tissues than variations during the early phase. In the present study, 319 
repeating the analyses after removing data for dogs with delayed phase images >240s after 320 
administration of contrast did not alter the significance of results of statistical tests. Nevertheless, 321 
patient factors and variations in timing of CT image acquisition will have affected the degree of 322 
enhancement of masses in post-contrast images, and may have contributed to the overlap 323 
observed between CT features of the hepatic and splenic masses in the present study.  324 
Automatic triggering of the CT acquisition, based on attenuation within a region of interest (e.g. 325 
the abdominal aorta) exceeding a threshold, is a software feature of CT scanners that can be used 326 
to increase precision in the timing of post-contrast images. Automatic triggering of the CT 327 
acquisition was not utilized for the present study. A test bolus technique has been employed for 328 
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dual-phase CT studies of dogs with suspected portosystemic shunting37,38 and insulinoma.39   329 
This technique enables optimal timing of the vascular phases of a multi-phase CT acquisition, 330 
but it requires an additional scan and image data analysis36, so is more time-consuming, which is 331 
disadvantageous for routine abdominal examinations. Recently, dual-phase CT of conscious 332 
sedated and unsedated dogs was described using fixed time delays equal to injection duration for 333 
HAP images and 40s for PVP images.40 Quality of images obtained was judged to be good or 334 
excellent in 72% dogs. Poor quality scans were primarily the result of motion blur or other 335 
artifacts; in only one instance was the HAP missed.40 Use of fixed time delays is a pragmatic 336 
approach for routine abdominal CT studies, although test bolus or automatic triggering methods 337 
enable CT scans to be acquired with a more accurately defined vascular phases.  338 
On the basis of these results, it may be concluded that the dual-phase protocol we employed for 339 
CT of dogs with hepatic or splenic masses provides limited specific diagnostic information. 340 
Variability in contrast delivery to masses and relatively low numbers of subjects limit the 341 
statistical power of the study. It is possible that significant associations between CT signs and 342 
diagnosis would be detected if larger numbers of subjects were studied under more consistent 343 
conditions, hence further studies are warranted.   344 
 17 
Table 1. Size, attenuation, and post-contrast enhancement characteristics of malignant and non-345 
malignant hepatic masses 346 
 Malignant 
(n=14) 
Non-malignant 
(n=10) 
 
P-value 
Maximum transverse dimension (mm) 61 (15 - 695) 60 (32 - 345) 0.95 
Mean hepatic parenchymal 
attenuation (HU) 
60 (53 - 75) 71 (49 - 79) 0.13 
Pre-contrast attenuation  (HU) 46 (32 - 68) 60 (26 - 69) 0.32 
Relative attenuation (HU) -13 (-28 - -3) -16 (-35 - -2) 0.75 
Early post-contrast attenuation (HU) 83 (42 - 152) 95 (22 - 125) 0.77 
Early enhancement   (HU) 31 (2 - 113) 42 (-4 - 65) 0.77 
Delayed post-contrast attenuation  
(HU) 
77 (42 - 120) 99 (25 - 121) 0.62 
Delayed enhancement  (HU)  27 (1 - 81) 34 (-1 - 53) 0.98 
Contrast accumulation (HU) -3 (-32 - 20) -5 (-23 - 52) 0.64 
 347 
Values are median (range); HU, Hounsfield units348 
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Table 2.  Descriptive features of malignant and non-malignant hepatic masses 349 
 Malignant 
(n=14) 
Non-Malignant 
(n=10) 
LR 95% CI 
Distinct margins  7 (64%) 4 (36%) 2.0 0.5-3.1 
Indistinct margins  7 (54%) 6 (46%) 0.8 0.4-1.7 
Homogeneous  8 (67%) 4 (33%) 1.4 0.6-3.5 
Heterogeneous 6 (50%) 6 (50%) 0.7 0.3-1.6 
Capsular distortion 12 (60%) 8 (40%) 1.1 0.7-1.6 
Generalized enhancement 12 (60%) 8 (40%) 1.1 0.7-1.6 
Peripheral enhancement  2 (50%) 2 (50%) 0.7 0.1-4.3 
Peritoneal fluid 4 (57%) 3 (43%) 0.9 0.3-3.2 
Mineralization within mass 3 (75%) 1 (25%) 2.1 0.3-17.7 
Abnormal local lymph nodes  11 (65%) 6 (35%) 1.3 0.7-2.3 
 350 
LR, Likelihood ratio associated with malignancy351 
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Table 3. Size, attenuation, and post-contrast enhancement characteristics of malignant and 353 
non-malignant splenic masses 354 
 Malignant 
(n=18) 
Non-malignant 
(n=13) 
 
P-value 
Maximum transverse dimension (mm) 69 (12 - 204) 73 (19 - 173) 0.28 
Mean splenic parenchymal attenuation  
(HU) 
53 (19 - 76) 61 (35 - 67) 0.18 
Pre-contrast attenuation (HU) 43 (-3 - 55) 49 (12 - 73) 0.12 
Relative attenuation (HU) -6 (-30 - 35) -2 (-52 - 20) 0.47 
Early post-contrast attenuation (HU) 63 (0 - 106) 73 (14 - 119) 0.36 
Early enhancement (HU) 20 (0 - 69) 20 (-3 - 64) 0.67 
Delayed post-contrast attenuation  
(HU) 
73 (0 - 120) 81 (16 - 112) 0.98 
Delayed enhancement (HU)  28 (0 - 82) 30 (4 - 57) 0.50 
Contrast accumulation (HU) 10 (-11 - 56) 3 (-7 - 27) 0.56 
 355 
Values are median (range); HU, Hounsfield units356 
  357 
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Table 4.  Descriptive features of malignant and non-malignant splenic masses 358 
 Malignant 
(n=18) 
Non-Malignant 
(n=13) 
LR 95% CI 
Distinct margins  6 (43%) 8 (57) 0.5 0.2-1.2 
Indistinct margins  12 (71%) 5 (29%) 1.7 0.8-3.7 
Homogeneous  5 (56%) 4 (44%) 0.9 0.3-2.7 
Heterogeneous 13 (59%) 9 (41%) 1.0 0.6-1.7 
Capsular distortion 17 (59%) 12 (41%) 1.0 0.8-1.2 
Generalized enhancement 16 (57%) 12 (43%) 0.9 0.8-1.2 
Peripheral enhancement  2 (67%) 1 (33%) 1.4 0.1-14.3 
Peritoneal fluid 12 (60%) 8 (40% 1.1 0.6-1.9 
Mineralization within mass 1 (100%) 0 (0%) 2.2 0.1-50.3 
Abnormal local lymph nodes  6 (55%) 5 (45%) 0.9 0.3-2.2 
 359 
LR, Likelihood ratio associated with malignancy360 
  361 
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Table 5. Pre- and post-contrast features of hepatocellular carcinoma, adenoma, and nodular 362 
hyperplasia 363 
 Hepatocellular 
carcinoma  
(n=9) 
Adenoma 
(n=6) 
Nodular 
hyperplasia 
(n=3)  
 
Pre Contrast    
  Hypoattenuation  5 (56%) 5 (83%) 2 (67%) 
  Isoattenuation  4 (44%) 1 (17%) 1 (33%) 
  Homogenous 3 (33%) 2 (33%) 2 (67%) 
  Heterogeneous  6 (66%) 4 (66%) 1 (33%) 
Early Phase    
  Slight enhancement  2 (22%) 1 (17%) 2 (67%) 
  Marked enhancement  7 (78%) 5 (83% 1 (33%) 
  Generalized  7 (78%) 6 (100%) 2 (67%) 
  Peripheral  2 (22%) 0  1 (33%) 
Late Phase    
  Slight enhancement  2 (22%) 0 2 (67%) 
  Marked enhancement  7 (78%) 6 (100%) 1 (33%) 
  Contrast accumulation 2 (22%) 0 1 (33%) 
  Lack of contrast 
accumulation 
7 (78%) 6 (100%) 2 (67%) 
  364 
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Table 6. Pre- and post-contrast features of splenic hemangiosarcoma, hematoma, and nodular 365 
hyperplasia 366 
 Hemangiosarcoma 
(n=13) 
Hematoma 
(n=8) 
Nodular 
hyperplasia 
(n=5) 
 
Pre Contrast    
  Hypoattenuation  4 (31%) 2 (25%) 3 (60%) 
  Isoattenuation  8 (62%) 5 (63%) 2 (40%) 
  Hyperattenuation 1 (7%) 1 (12%) 0 
  Homogenous 4 (31%) 3 (38%) 1 (20%) 
  Heterogeneous  9 (69%) 5 (62%) 4 (80%) 
Early Phase    
  Slight enhancement  2 (15%) 5 (62%) 0 
  Marked enhancement  11 (85%) 3 (38%) 5 (100%) 
  Generalized  12 (92%) 7 (88%) 5 (100% 
  Peripheral  1 (7%) 1 (12%) 0 
Late Phase    
  Slight enhancement  1 (7%) 3 (38%) 0 
  Marked enhancement  12 (92%) 5 (62%) 5 (100% 
  Contrast accumulation 10 (77%) 8 (100%) 2 (40%) 
  Lack of contrast 
accumulation 
3 (23%) 0 3 (60%) 
  367 
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Legends 476 
Figure 1. Examples of dual-phase CT images of hepatic masses in dogs. A) Hepatocellular carcinoma; B) 477 
adenoma (between arrows); C) nodular hyperplasia (between arrowheads). In each instance images are pre-478 
contrast (left), early phase (middle) and delayed phase (right).  Each of these lesions has slightly lower 479 
attenuation and is heterogeneous compared to surrounding hepatic parenchyma in pre-contrast images, and show 480 
marked, generalized enhancement in the early phase images that persists in delayed phase images. Multiple 481 
masses with similar features are present throughout the liver in the dog with hepatocellular carcinoma. Window 482 
350HU, level 50HU.  483 
 484 
 485 
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Figure 2. Examples of multi-phase CT images of splenic masses in dogs. A) hemangiosarcoma (between 486 
arrowheads); B) hematoma (between arrows); C) nodular hyperplasia (within dotted line). Each of these lesions 487 
has slightly lower attenuation and is heterogeneous compared to surrounding hepatic parenchyma in pre-contrast 488 
images, and show marked, generalized heterogeneous enhancement in early phase images that increases in 489 
delayed phase images as a result of contrast accumulation. Foci of marked local contrast accumulation are 490 
evident in the hyperplastic mass (arrowhead) compatible with contrast in large vascular spaces.28  Multiple 491 
segmental lesions affecting the kidneys in the dog with hemangiosarcoma are compatible with infarcts. H, 492 
peritoneal hematoma. Window 350HU, level 50HU.  493 
 494 
